IL161224A0 - Pharmaceutical compositions comprising 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide - Google Patents

Pharmaceutical compositions comprising 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide

Info

Publication number
IL161224A0
IL161224A0 IL16122497A IL16122497A IL161224A0 IL 161224 A0 IL161224 A0 IL 161224A0 IL 16122497 A IL16122497 A IL 16122497A IL 16122497 A IL16122497 A IL 16122497A IL 161224 A0 IL161224 A0 IL 161224A0
Authority
IL
Israel
Prior art keywords
phenylisoxazol
benzenesulfonamide
methyl
pharmaceutical compositions
pharmaceutical
Prior art date
Application number
IL16122497A
Other languages
English (en)
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of IL161224A0 publication Critical patent/IL161224A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L23/00—Details of semiconductor or other solid state devices
    • H01L23/34—Arrangements for cooling, heating, ventilating or temperature compensation ; Temperature sensing arrangements
    • H01L23/40—Mountings or securing means for detachable cooling or heating arrangements ; fixed by friction, plugs or springs
    • H01L23/4006—Mountings or securing means for detachable cooling or heating arrangements ; fixed by friction, plugs or springs with bolts or screws
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L23/00—Details of semiconductor or other solid state devices
    • H01L23/34—Arrangements for cooling, heating, ventilating or temperature compensation ; Temperature sensing arrangements
    • H01L23/42—Fillings or auxiliary members in containers or encapsulations selected or arranged to facilitate heating or cooling
    • H01L23/427—Cooling by change of state, e.g. use of heat pipes
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L2924/00—Indexing scheme for arrangements or methods for connecting or disconnecting semiconductor or solid-state bodies as covered by H01L24/00
    • H01L2924/0001—Technical content checked by a classifier
    • H01L2924/0002—Not covered by any one of groups H01L24/00, H01L24/00 and H01L2224/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Power Engineering (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Computer Hardware Design (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
IL16122497A 1996-08-14 1997-08-12 Pharmaceutical compositions comprising 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide IL161224A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2437896P 1996-08-14 1996-08-14
IL12825597A IL128255A (en) 1996-08-14 1997-08-12 Crystal form of –4 [–5 methyl –– 3 phenylisoxazole ––4yl] benzenesulfonamide
PCT/US1997/015126 WO1998006708A1 (fr) 1996-08-14 1997-08-12 Forme cristalline du 4-[5-methyl-3phenylisoxanol-4yl] benzenesulfonamide

Publications (1)

Publication Number Publication Date
IL161224A0 true IL161224A0 (en) 2004-09-27

Family

ID=21820280

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16122497A IL161224A0 (en) 1996-08-14 1997-08-12 Pharmaceutical compositions comprising 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide
IL12825597A IL128255A (en) 1996-08-14 1997-08-12 Crystal form of –4 [–5 methyl –– 3 phenylisoxazole ––4yl] benzenesulfonamide

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL12825597A IL128255A (en) 1996-08-14 1997-08-12 Crystal form of –4 [–5 methyl –– 3 phenylisoxazole ––4yl] benzenesulfonamide

Country Status (39)

Country Link
US (2) US6441014B2 (fr)
EP (2) EP0920422B1 (fr)
JP (2) JP3631763B2 (fr)
KR (1) KR100383148B1 (fr)
CN (1) CN1205193C (fr)
AP (1) AP1055A (fr)
AR (1) AR009244A1 (fr)
AT (1) ATE228117T1 (fr)
AU (1) AU722072B2 (fr)
BG (1) BG64259B1 (fr)
BR (1) BR9711151A (fr)
CA (1) CA2264104A1 (fr)
CZ (1) CZ297679B6 (fr)
DE (1) DE69717281T2 (fr)
DK (1) DK0920422T3 (fr)
EA (2) EA003754B1 (fr)
EE (1) EE04237B1 (fr)
ES (1) ES2188971T3 (fr)
GE (1) GEP20022636B (fr)
HK (1) HK1023125A1 (fr)
HU (1) HUP0400923A3 (fr)
IL (2) IL161224A0 (fr)
IS (1) IS1989B (fr)
LT (1) LT4551B (fr)
LV (1) LV12274B (fr)
NO (1) NO312461B1 (fr)
NZ (1) NZ334132A (fr)
OA (1) OA11298A (fr)
PL (1) PL191313B1 (fr)
PT (1) PT920422E (fr)
RO (1) RO120771B1 (fr)
RS (1) RS49671B (fr)
SI (1) SI9720059B (fr)
SK (1) SK283558B6 (fr)
TR (1) TR199900298T2 (fr)
TW (1) TW527350B (fr)
UA (1) UA52684C2 (fr)
WO (1) WO1998006708A1 (fr)
ZA (1) ZA977314B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3631763B2 (ja) * 1996-08-14 2005-03-23 ジー・ディー・サール・アンド・カンパニー ４―［５―メチル―３―フェニルイソキサゾル―４―イル］ベンゼンスルホンアミドの結晶形
US6887893B1 (en) * 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
GB9810920D0 (en) * 1998-05-21 1998-07-22 Merck Sharp & Dohme Therapeutic use
AU5467699A (en) * 1998-08-07 2000-02-28 Chiron Corporation Substituted isoxazole as estrogen receptor modulators
AU1398899A (en) * 1998-11-12 2000-06-05 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with centrally acting analgesics
CN1349423A (zh) * 1999-03-01 2002-05-15 奥索-麦克尼尔药品公司 包含曲马多物质和选择性cox－2抑制剂药物的组合物
SK286621B6 (sk) * 1999-08-20 2009-02-05 Ortho-Mcneil Pharmaceutical, Inc. Farmaceutický prostriedok obsahujúci kombináciu tramadolového materiálu a antikonvulzívneho činidla, táto kombinácia a jej použitie na výrobu liečiva
EP1212051A4 (fr) * 1999-08-27 2004-03-31 Merck & Co Inc Methode de traitement ou de prevention de la prostatite chronique ou du syndrome de la douleur pelvienne chronique
DE10032132A1 (de) * 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung
ES2453164T3 (es) * 2001-08-15 2014-04-04 Pharmacia & Upjohn Company Llc Cristales que incluyen una sal de ácido málico de N-[2-(dietilamino)etil]-5-[(5-fluoro-1,2-dihidro-2-oxo-3H-indol-3-iliden)metil]-2,4-dimetil-1H-pirrol-3-carboxamida, procedimientos para su preparación y sus composiciones
US20070072921A1 (en) * 2002-07-26 2007-03-29 Talley John J Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide
AU2003238668A1 (en) 2003-04-04 2004-10-25 Hetero Drugs Limited Novel crystalline forms of valdecoxib
ES2275218T3 (es) 2003-05-07 2007-06-01 Osteologix A/S Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
US20050182113A1 (en) * 2003-12-30 2005-08-18 Venkataraman Sundaram Method for preparing diaryl-substituted isoxazole compounds
US20050272787A1 (en) * 2004-05-19 2005-12-08 Eswaraiah Sajja Process for preparing crystalline form A of valdecoxib
WO2005120499A1 (fr) * 2004-06-10 2005-12-22 Chandiran Thakashinamoorthy Forme de valdecoxib adaptee pour des compositions pharmaceutiques
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
PL1612203T3 (pl) * 2004-06-28 2007-12-31 Gruenenthal Gmbh Krystaliczne postacie chlorowodorku (-)-(1R,2R)-3-(3-dimetyloamino-1-etylo-2-metylo-propylo)fenolu
KR100591786B1 (ko) 2004-10-19 2006-06-26 휴먼팜 주식회사 프란루카스트를 함유하는 약학적 조성물 및 이의 제조 방법
EA200702558A1 (ru) 2005-05-20 2008-06-30 Янссен Фармацевтика Н. В. Способ получения производных сульфамида
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
AU2007253814A1 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
EA018567B1 (ru) 2008-06-23 2013-08-30 Янссен Фармацевтика Нв Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CN103172583A (zh) * 2013-03-07 2013-06-26 深圳市资福药业有限公司 一种制备帕瑞昔布的方法
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
US10028904B2 (en) 2014-12-04 2018-07-24 Wisconsin Alumni Research Foundation Transdermal cannabinoid formulations
CN114441666B (zh) * 2020-11-05 2024-02-27 成都百裕制药股份有限公司 一种4-(5-甲基-3-苯基-4-异恶唑)苯磺酰氯中杂质的检测方法
US20240165148A1 (en) 2021-03-15 2024-05-23 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
ES2183935T3 (es) * 1995-02-13 2003-04-01 Searle & Co Isoxazoles sustituidos para el tratamiento de la inflamacion.
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
JP3631763B2 (ja) * 1996-08-14 2005-03-23 ジー・ディー・サール・アンド・カンパニー ４―［５―メチル―３―フェニルイソキサゾル―４―イル］ベンゼンスルホンアミドの結晶形
AU2003238668A1 (en) * 2003-04-04 2004-10-25 Hetero Drugs Limited Novel crystalline forms of valdecoxib
US20050272787A1 (en) * 2004-05-19 2005-12-08 Eswaraiah Sajja Process for preparing crystalline form A of valdecoxib

Also Published As

Publication number Publication date
LV12274A (lv) 1999-05-20
HUP0400923A2 (hu) 2004-08-30
ZA977314B (en) 1998-08-14
NO990541L (no) 1999-02-05
EE04237B1 (et) 2004-02-16
AP1055A (en) 2002-04-04
GEP20022636B (en) 2002-02-25
SK13699A3 (en) 1999-07-12
BG64259B1 (bg) 2004-07-30
IL128255A0 (en) 1999-11-30
PT920422E (pt) 2003-03-31
ATE228117T1 (de) 2002-12-15
LV12274B (en) 1999-09-20
SI9720059B (sl) 2011-11-30
RS49671B (sr) 2007-11-15
AR009244A1 (es) 2000-04-12
WO1998006708A1 (fr) 1998-02-19
NO312461B1 (no) 2002-05-13
SI9720059A (sl) 1999-12-31
HK1023125A1 (en) 2000-09-01
CN1205193C (zh) 2005-06-08
TR199900298T2 (xx) 1999-05-21
TW527350B (en) 2003-04-11
EE9900053A (et) 1999-08-16
EA003754B1 (ru) 2003-08-28
EA199900200A1 (ru) 1999-06-24
EP0920422A1 (fr) 1999-06-09
DE69717281T2 (de) 2003-09-04
JP2000506542A (ja) 2000-05-30
BG103155A (en) 1999-11-30
YU7499A (sh) 2000-03-21
IS1989B (is) 2005-02-15
CA2264104A1 (fr) 1998-02-19
IL128255A (en) 2004-06-20
HUP0400923A3 (en) 2007-11-28
EA200000891A1 (ru) 2001-02-26
OA11298A (en) 2003-10-22
CN1233243A (zh) 1999-10-27
US6441014B2 (en) 2002-08-27
CZ33499A3 (cs) 1999-06-16
ES2188971T3 (es) 2003-07-01
IS4961A (is) 1999-01-29
NZ334132A (en) 2000-06-23
EP0920422B1 (fr) 2002-11-20
EP1283203A1 (fr) 2003-02-12
AP9901458A0 (en) 1999-03-31
UA52684C2 (uk) 2003-01-15
CZ297679B6 (cs) 2007-03-07
US20010003752A1 (en) 2001-06-14
US7135489B2 (en) 2006-11-14
DE69717281D1 (de) 2003-01-02
PL191313B1 (pl) 2006-04-28
US20030004200A1 (en) 2003-01-02
JP2005015497A (ja) 2005-01-20
DK0920422T3 (da) 2003-03-17
LT99024A (en) 1999-07-26
JP3631763B2 (ja) 2005-03-23
PL331607A1 (en) 1999-08-02
BR9711151A (pt) 1999-08-17
LT4551B (lt) 1999-10-25
KR100383148B1 (ko) 2003-05-09
KR20000029994A (ko) 2000-05-25
SK283558B6 (sk) 2003-09-11
AU4093697A (en) 1998-03-06
EA001472B1 (ru) 2001-04-23
NO990541D0 (no) 1999-02-05
RO120771B1 (ro) 2006-07-28
AU722072B2 (en) 2000-07-20

Similar Documents

Publication Publication Date Title
IL161224A0 (en) Pharmaceutical compositions comprising 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide
IL125849A (en) Substituted benzenesulfonamide derivatives, their preparation and pharmaceutical compositions comprising them
HK1041224A1 (zh) 新的藥物製劑
EG24118A (en) Pharmaceutical compositions
ZA982872B (en) Pharmaceutical formulation
PL339461A1 (en) Orally administered compositions containing levosimendane
GB9616672D0 (en) Pharmaceutical compositions
AU8107998A (en) Pharmaceutical compositions
GB9610359D0 (en) Pharmaceutical compositions
AP9901657A0 (en) Pharmaceutical compositions
HUP0104549A3 (en) Imidazo-pyridine sulfonamide derivatives and pharmaceutical compositions thereof
GB9723985D0 (en) Pharmaceutical compositions
GB9622681D0 (en) Pharmaceutical compositions
GB9606429D0 (en) Pharmaceutical compositions
GB9818927D0 (en) Pharmaceutical formulation
GB9709739D0 (en) Pharmaceutical formulation
GB9613457D0 (en) Pharmaceutical compositions
GB9618376D0 (en) Pharmaceutical compositions
GB9822333D0 (en) Pharmaceutical formulation
GB9610136D0 (en) Pharmaceutical compositions
GB9817470D0 (en) Pharmaceutical formulation
GB9921495D0 (en) Pharmaceutical compositions
GB9802617D0 (en) Pharmaceutical formulation
GB9603141D0 (en) Pharmaceutical formulation
GB9606586D0 (en) Pharmaceutical compositions